Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
Brain Implant Startups Aim to Bring Vision Back to The Blind [Yahoo! Finance]
Vivani Medical, Inc. (NASDAQ: VANI) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
Vivani Medical obtains Australian approval to begin GLP-1 implant trial [Yahoo! Finance]